Evolving therapeutic goals in Crohn's disease management
The main objectives in Crohn's disease are to avoid disease complications and preserve the patient's quality of life. Early disease control and close monitoring with specific targets to reach might be the only way to change the disease course. In two decades, we have moved from clinical response to full remission (clinical and endoscopic remission) requiring a tight monitoring of both symptoms and objective signs of inflammation. This review summarizes the concepts of tight control and treat-to-target and their potential for disease modification.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
United European gastroenterology journal - 8(2020), 2 vom: 27. März, Seite 133-139 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chateau, Thomas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
51333-22-3 |
|---|
| Anmerkungen: |
Date Completed 21.06.2021 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/2050640619887316 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307989372 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307989372 | ||
| 003 | DE-627 | ||
| 005 | 20240328233901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/2050640619887316 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1352.xml |
| 035 | |a (DE-627)NLM307989372 | ||
| 035 | |a (NLM)32213074 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chateau, Thomas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evolving therapeutic goals in Crohn's disease management |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2021 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The main objectives in Crohn's disease are to avoid disease complications and preserve the patient's quality of life. Early disease control and close monitoring with specific targets to reach might be the only way to change the disease course. In two decades, we have moved from clinical response to full remission (clinical and endoscopic remission) requiring a tight monitoring of both symptoms and objective signs of inflammation. This review summarizes the concepts of tight control and treat-to-target and their potential for disease modification | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Crohn's disease | |
| 650 | 4 | |a Tight control | |
| 650 | 4 | |a treat-to-target | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Inflammation Mediators |2 NLM | |
| 650 | 7 | |a Budesonide |2 NLM | |
| 650 | 7 | |a 51333-22-3 |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 700 | 1 | |a Peyrin-Biroulet, Laurent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t United European gastroenterology journal |d 2013 |g 8(2020), 2 vom: 27. März, Seite 133-139 |w (DE-627)NLM237284804 |x 2050-6414 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:2 |g day:27 |g month:03 |g pages:133-139 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/2050640619887316 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 2 |b 27 |c 03 |h 133-139 | ||